ProKidney (PROK) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$818,000.00

Revenue (quarter)

$150,000.00

Revenue growth (year over year)

−32.13%

Gross profit (trailing twelve months)

$818,000.00

Gross margin

100.00%

Net income (trailing twelve months)

−$165.8M

Net income (quarter)

−$46.4M

Net income growth (year over year)

−25.62%

Net margin

−20263.08%

Return on equity

—

EPS (trailing twelve months)

−$0.55

Book value per share

−$2.92

P/E (trailing twelve months)

—

Price to book

2.13

Debt to assets

10.51%

Payout ratio

—

Dividend yield

—

Company profile

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

• Is ProKidney (PROK) profitable?

  No. ProKidney reported a net loss of $165.8M over the trailing twelve months.

• How much revenue does ProKidney (PROK) make?

  ProKidney generated $818,000.00 in revenue over the trailing twelve months, down 32.13% year over year.

• How do I buy stock in ProKidney (PROK)?

  PROK trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.